ArticleThe journal of allergy and clinical immunology. In practice2021
Performance of Eosinophil Cationic Protein as a Biomarker in Asthmatic Children.
Article in The journal of allergy and clinical immunology. In practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Proteomic Identification of Plasma Biomarkers of Response to IL-5 Inhibitor Biologics in Healthy Subjects.Clinical and translational science · 2025Trial
- Serum Eosinophil Cationic Protein (ECP) as a Biomarker for Distinguishing Pediatric Allergic Airway Diseases.International journal of molecular sciences · 2026Article
- Recent advances in biomarkers for efficacy assessment in allergen-specific immunotherapy.Frontiers in allergy · 2026Review
- Asthma Phenotypes and Biomarkers.Respiratory care · 2025Review
- Cure for the itch: current clinical standards and therapies in allergic eczema.Frontiers in allergy · 2025Review
- Eosinophilic cationic protein and D-Dimer are potential biomarkers to predict response to antihistamines but not to omalizumab in chronic spontaneous urticaria.The Libyan journal of medicine · 2024Article
- Evaluation of the Correlation Between Nasal Secretion ECP-MPO Test Papers and Immune Markers in Subcutaneous Immunotherapy of Dust Mites.Journal of asthma and allergy · 2024Article
- Prediction of Asthma Exacerbations in Children.Journal of personalized medicine · 2023Review
- Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab.Life (Basel, Switzerland) · 2023Article
- Eosinophils and basophils in severe fever with thrombocytopenia syndrome patients: Risk factors for predicting the prognosis on admission.PLoS neglected tropical diseases · 2022Article
- Asthma and Allergy: Unravelling a Tangled Relationship with a Focus on New Biomarkers and Treatment.International journal of molecular sciences · 2022Review
- Heterogeneous Condition of Asthmatic Children Patients: A Narrative Review.Children (Basel, Switzerland) · 2022Review
- Long Term Effectiveness of Mepolizumab in the Treatment of Chronic Eosinophilic Pneumonia.Open respiratory archivesArticle
- Serum Eosinophil Cationic Protein in Urticaria Patients with Anti-Iranian journal of parasitologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundAlthough blood eosinophils are a frequently used marker of type 2 inflammation in children with asthma, their sensitivity is relatively poor. Additional markers of type 2 inflammation are needed.
objectiveWe hypothesized that plasma concentrations of eosinophil cationic protein (ECP), a marker of eosinophil activation, would be useful for detection of type 2 inflammation and would predict poorer asthma outcomes over 1 year.
methodsChildren and adolescents 6 through 17 years (N = 256) with confirmed asthma completed a baseline visit and a follow-up visit at 12 months. A subset also underwent systemic corticosteroid responsiveness testing with intramuscular triamcinolone. Outcome measures at 12 months included uncontrolled asthma, lung function, and asthma exacerbations treated with systemic corticosteroids.
resultsPlasma ECP concentrations ranged from 0.03 to 413.61 ng/mL (median, 6.95 ng/mL) and were consistently associated with other markers of type 2 inflammation. At baseline, children in the highest ECP tertile had poorer asthma control, more airflow limitation, and more exacerbations, but also had greater symptom improvement with intramuscular triamcinolone. At 12 months, associations between the highest ECP tertile and exacerbations, but not lung function or asthma control, persisted after covariate adjustment. However, the sensitivity of ECP was modest and was not markedly different from that of blood eosinophil counts.
conclusionPlasma ECP concentrations may be a useful marker of type 2 inflammation in children and may help identify those children at highest risk for recurrent exacerbations who could benefit from corticosteroid treatment. However, additional markers may be needed to improve sensitivity for outcome detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.